Latest Update: Impact of current COVID-19 situation has been considered in this report while making the analysis.
Global Antihormonal Cancer Therapies Market by Type (Radiations, Drugs, Surgeries, Others), By Application (Breast Cancer, Prostate Cancer, Other) And By Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa), Forecast From 2022 To 2030-report

Global Antihormonal Cancer Therapies Market by Type (Radiations, Drugs, Surgeries, Others), By Application (Breast Cancer, Prostate Cancer, Other) And By Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa), Forecast From 2022 To 2030

Report ID: 168333 3300 Medical Devices & Consumables 377 230 Pages 4.7 (39)
                                          

The global antihormonal cancer therapies market is expected to grow at a CAGR of 5.5% during the forecast period, from 2021 to 2030. The market is driven by factors such as increasing incidence of breast and prostate cancer, rising awareness about the benefits of antihormonal therapy, and technological advancements in the field. The global antihormonal cancer therapies market is segmented on the basis of type into radiations, drugs, and surgeries; on the basis of application into breast cancer and prostate cancer; and on the basis of region into North America, Latin America, Europe, Asia Pacific (APAC), Middle East & Africa (MEA). The radiations segment accounted for a major share in 2018 owing to its high efficacy rate. The drugs segment is expected to grow at a higher CAGR during the forecast period owing to its low cost-effectiveness ratio. -The global Antihormonal Cancer Therapies market is expected to grow at a CAGR of XX% during the forecast period. -The increasing prevalence of cancer globally is one of the major factors driving the growth of this market. -Increasing awareness about cancer and its treatment options among people is also driving the growth of this market.

Industry Growth Insights published a new data on “Antihormonal Cancer Therapies Market”. The research report is titled “Antihormonal Cancer Therapies Market research by Types (Radiations, Drugs, Surgeries, Others), By Applications (Breast Cancer, Prostate Cancer, Other), By Players/Companies AstraZeneca, Novartis, Pfizer, Sanofi, Takeda, Roche, Amgen, Samyang Biopharmaceuticals, Tolmar, Bluebird Bio, Bristol-Myers Squibb, Exelixis, Guardant Health, Illumina”.

Scope Of The Report

Report Attributes

Report Details

Report Title

Antihormonal Cancer Therapies Market Research Report

By Type

Radiations, Drugs, Surgeries, Others

By Application

Breast Cancer, Prostate Cancer, Other

By Companies

AstraZeneca, Novartis, Pfizer, Sanofi, Takeda, Roche, Amgen, Samyang Biopharmaceuticals, Tolmar, Bluebird Bio, Bristol-Myers Squibb, Exelixis, Guardant Health, Illumina

Regions Covered

North America, Europe, APAC, Latin America, MEA

Base Year

2021

Historical Year

2019 to 2020 (Data from 2010 can be provided as per availability)

Forecast Year

2030

Number of Pages

230

Number of Tables & Figures

161

Customization Available

Yes, the report can be customized as per your need.


Global Antihormonal Cancer Therapies Industry Outlook


Global Antihormonal Cancer Therapies Market Report Segments:

The global Antihormonal Cancer Therapies market is segmented on the basis of:

Types

Radiations, Drugs, Surgeries, Others

The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.

Applications

Breast Cancer, Prostate Cancer, Other

The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.

Some of the companies that are profiled in this report are:

  1. AstraZeneca
  2. Novartis
  3. Pfizer
  4. Sanofi
  5. Takeda
  6. Roche
  7. Amgen
  8. Samyang Biopharmaceuticals
  9. Tolmar
  10. Bluebird Bio
  11. Bristol-Myers Squibb
  12. Exelixis
  13. Guardant Health
  14. Illumina

Global Antihormonal Cancer Therapies Market Overview


Highlights of The Antihormonal Cancer Therapies Market Report:

  1. The market structure and projections for the coming years.
  2. Drivers, restraints, opportunities, and current trends of market.
  3. Historical data and forecast.
  4. Estimations for the forecast period 2030.
  5. Developments and trends in the market.
  6. By Type:

    1. Radiations
    2. Drugs
    3. Surgeries
    4. Others
  1. By Application:

    1. Breast Cancer
    2. Prostate Cancer
    3. Other
  1. Market scenario by region, sub-region, and country.
  2. Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
  3. Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
  4. Government Policies, Macro & Micro economic factors are also included in the report.

We have studied the Antihormonal Cancer Therapies Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.

Regional Analysis

  • North America
  • Europe
  • Asia Pacific
  • Middle East & Africa
  • Latin America

Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.

The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.

How you may use our products:

  • Correctly Positioning New Products
  • Market Entry Strategies
  • Business Expansion Strategies
  • Consumer Insights
  • Understanding Competition Scenario
  • Product & Brand Management
  • Channel & Customer Management
  • Identifying Appropriate Advertising Appeals

Global Antihormonal Cancer Therapies Market Statistics

8 Reasons to Buy This Report

  1. Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
  2. Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
  3. Implemented Robust Methodology to Prepare the Report
  4. Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
  5. Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
  6. Provides Information About the Top-winning Strategies Implemented by Industry Players.
  7. In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
  8. Customization of the Report Available

Frequently Asked Questions?


There are a number of different types of anti-hormonal cancer therapies, which work by blocking the action of hormones in the body. This can lead to the death of cancer cells.

Some of the key players operating in the antihormonal cancer therapies market are AstraZeneca, Novartis, Pfizer, Sanofi, Takeda, Roche, Amgen, Samyang Biopharmaceuticals, Tolmar, Bluebird Bio, Bristol-Myers Squibb, Exelixis, Guardant Health, Illumina.

The antihormonal cancer therapies market is expected to register a CAGR of 5.5%.

                                            
1. Executive Summary

2. Assumptions and Acronyms Used

3. Research Methodology

4. Antihormonal Cancer Therapies Market Overview
   4.1. Introduction
      4.1.1. Market Taxonomy
      4.1.2. Market Definition
   4.2. Macro-Economic Factors
      4.2.1. Industry Outlook
   4.3. Antihormonal Cancer Therapies Market Dynamics
      4.3.1. Market Drivers
      4.3.2. Market Restraints
      4.3.3. Opportunity
      4.3.4. Market Trends
   4.4. Antihormonal Cancer Therapies Market - Supply Chain
   4.5. Global Antihormonal Cancer Therapies Market Forecast
      4.5.1. Antihormonal Cancer Therapies Market Size (US$ Mn) and Y-o-Y Growth
      4.5.2. Antihormonal Cancer Therapies Market Size (000’ Units) and Y-o-Y Growth
      4.5.3. Antihormonal Cancer Therapies Market Absolute $ Opportunity

5. Global Antihormonal Cancer Therapies Market Analysis and Forecast by Type
   5.1. Market Trends
   5.2. Introduction
      5.2.1. Basis Point Share (BPS) Analysis by Type
      5.2.2. Y-o-Y Growth Projections by Type
   5.3. Antihormonal Cancer Therapies Market Size and Volume Forecast by Type
      5.3.1. Radiations
      5.3.2. Drugs
      5.3.3. Surgeries
      5.3.4. Others
   5.4. Absolute $ Opportunity Assessment by Type
   5.5. Market Attractiveness/Growth Potential Analysis by Type

6. Global Antihormonal Cancer Therapies Market Analysis and Forecast by Application
   6.1. Market Trends
   6.2. Introduction
      6.2.1. Basis Point Share (BPS) Analysis by Application
      6.2.2. Y-o-Y Growth Projections by Application
   6.3. Antihormonal Cancer Therapies Market Size and Volume Forecast by Application
      6.3.1. Breast Cancer
      6.3.2. Prostate Cancer
      6.3.3. Other
   6.4. Absolute $ Opportunity Assessment by Application
   6.5. Market Attractiveness/Growth Potential Analysis by Application

7. Global Antihormonal Cancer Therapies Market Analysis and Forecast by Sales Channel
   7.1. Market Trends
   7.2. Introduction
      7.2.1. Basis Point Share (BPS) Analysis by Sales Channel 
      7.2.2. Y-o-Y Growth Projections by Sales Channel
   7.3. Antihormonal Cancer Therapies Market Size and Volume Forecast by Sales Channel 
      7.3.1. Manufacturer/Distributor/Service Provider
      7.3.2. Aftermarket
   7.4. Absolute $ Opportunity Assessment by Sales Channel
   7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel

8. Global Antihormonal Cancer Therapies Market Analysis and Forecast by Region
   8.1. Market Trends
   8.2. Introduction
      8.2.1. Basis Point Share (BPS) Analysis by Region
      8.2.2. Y-o-Y Growth Projections by Region
   8.3. Antihormonal Cancer Therapies Market Size and Volume Forecast by Region
      8.3.1. North America
      8.3.2. Latin America
      8.3.3. Europe
      8.3.4. Asia Pacific
      8.3.5. Middle East and Africa (MEA)
   8.4. Absolute $ Opportunity Assessment by Region
   8.5. Market Attractiveness/Growth Potential Analysis by Region
   8.6. Global Antihormonal Cancer Therapies Demand Share Forecast, 2019-2026

9. North America Antihormonal Cancer Therapies Market Analysis and Forecast
   9.1. Introduction
      9.1.1. Basis Point Share (BPS) Analysis by Country
      9.1.2. Y-o-Y Growth Projections by Country
   9.2. North America Antihormonal Cancer Therapies Market Size and Volume Forecast by Country
      9.2.1. U.S.
      9.2.2. Canada
   9.3. Absolute $ Opportunity Assessment by Country
   9.4. North America Antihormonal Cancer Therapies Market Size and Volume Forecast by Application
      9.4.1. Breast Cancer
      9.4.2. Prostate Cancer
      9.4.3. Other
   9.5. Basis Point Share (BPS) Analysis by Application
   9.6. Y-o-Y Growth Projections by Application
   9.7. North America Antihormonal Cancer Therapies Market Size and Volume Forecast by Type
      9.7.1. Radiations
      9.7.2. Drugs
      9.7.3. Surgeries
      9.7.4. Others
   9.8. Basis Point Share (BPS) Analysis by Type
   9.9. Y-o-Y Growth Projections by Type
   9.10. Market Attractiveness/Growth Potential Analysis
      9.10.1. By Country
      9.10.2. By Product Type
      9.10.3. By Application
      9.10.4. By Sales Channel
   9.11. North America Antihormonal Cancer Therapies Demand Share Forecast, 2019-2026

10. Latin America Antihormonal Cancer Therapies Market Analysis and Forecast
   10.1. Introduction
      10.1.1. Basis Point Share (BPS) Analysis by Country
      10.1.2. Y-o-Y Growth Projections by Country
      10.1.3. Latin America Average Pricing Analysis
   10.2. Latin America Antihormonal Cancer Therapies Market Size and Volume Forecast by Country
      10.2.1. Brazil
      10.2.2. Mexico
      10.2.3. Rest of Latin America
   10.3. Absolute $ Opportunity Assessment by Country
   10.4. Latin America Antihormonal Cancer Therapies Market Size and Volume Forecast by Application
      10.4.1. Breast Cancer
      10.4.2. Prostate Cancer
      10.4.3. Other
   10.5. Basis Point Share (BPS) Analysis by Application
   10.6. Y-o-Y Growth Projections by Application
   10.7. Latin America Antihormonal Cancer Therapies Market Size and Volume Forecast by Type
      10.7.1. Radiations
      10.7.2. Drugs
      10.7.3. Surgeries
      10.7.4. Others
   10.8. Basis Point Share (BPS) Analysis by Type
   10.9. Y-o-Y Growth Projections by Type
   10.10. Market Attractiveness/Growth Potential Analysis
      10.10.1. By Country
      10.10.2. By Product Type
      10.10.3. By Application
      10.10.4. By Sales Channel
   10.11. Latin America Antihormonal Cancer Therapies Demand Share Forecast, 2019-2026

11. Europe Antihormonal Cancer Therapies Market Analysis and Forecast
   11.1. Introduction
      11.1.1. Basis Point Share (BPS) Analysis by Country
      11.1.2. Y-o-Y Growth Projections by Country
      11.1.3. Europe Average Pricing Analysis
   11.2. Europe Antihormonal Cancer Therapies Market Size and Volume Forecast by Country
      11.2.1. Germany
      11.2.2. France
      11.2.3. Italy
      11.2.4. U.K.
      11.2.5. Spain
      11.2.6. Russia
      11.2.7. Rest of Europe
   11.3. Absolute $ Opportunity Assessment by Country
   11.4. Europe Antihormonal Cancer Therapies Market Size and Volume Forecast by Application
      11.4.1. Breast Cancer
      11.4.2. Prostate Cancer
      11.4.3. Other
   11.5. Basis Point Share (BPS) Analysis by Application
   11.6. Y-o-Y Growth Projections by Application
   11.7. Europe Antihormonal Cancer Therapies Market Size and Volume Forecast by Type
      11.7.1. Radiations
      11.7.2. Drugs
      11.7.3. Surgeries
      11.7.4. Others
   11.8. Basis Point Share (BPS) Analysis by Type
   11.9. Y-o-Y Growth Projections by Type
   11.10. Market Attractiveness/Growth Potential Analysis
      11.10.1. By Country
      11.10.2. By Product Type
      11.10.3. By Application
      11.10.4. By Sales Channel
   11.11. Europe Antihormonal Cancer Therapies Demand Share, 2019-2026

12. Asia Pacific Antihormonal Cancer Therapies Market Analysis and Forecast
   12.1. Introduction
      12.1.1. Basis Point Share (BPS) Analysis by Country
      12.1.2. Y-o-Y Growth Projections by Country
      12.1.3. Asia Pacific Average Pricing Analysis
   12.2. Asia Pacific Antihormonal Cancer Therapies Market Size and Volume Forecast by Country
      12.2.1. China
      12.2.2. Japan
      12.2.3. South Korea
      12.2.4. India
      12.2.5. Australia
      12.2.6. Rest of Asia Pacific (APAC)
   12.3. Absolute $ Opportunity Assessment by Country
   12.4. Asia Pacific Antihormonal Cancer Therapies Market Size and Volume Forecast by Application
      12.4.1. Breast Cancer
      12.4.2. Prostate Cancer
      12.4.3. Other
   12.5. Basis Point Share (BPS) Analysis by Application
   12.6. Y-o-Y Growth Projections by Application
   12.7. Asia Pacific Antihormonal Cancer Therapies Market Size and Volume Forecast by Type
      12.7.1. Radiations
      12.7.2. Drugs
      12.7.3. Surgeries
      12.7.4. Others
   12.8. Basis Point Share (BPS) Analysis by Type
   12.9. Y-o-Y Growth Projections by Type
   12.10. Market Attractiveness/Growth Potential Analysis
      12.10.1. By Country
      12.10.2. By Product Type
      12.10.3. By Application
      12.10.4. By Sales Channel
   12.11. Asia Pacific Antihormonal Cancer Therapies Demand Share, 2019-2026

13. Middle East & Africa Antihormonal Cancer Therapies Market Analysis and Forecast
   13.1. Introduction
      13.1.1. Basis Point Share (BPS) Analysis by Country
      13.1.2. Y-o-Y Growth Projections by Country
      13.1.3. Asia Pacific Average Pricing Analysis
   13.2. Middle East & Africa Antihormonal Cancer Therapies Market Size and Volume Forecast by Country
      13.2.1. Saudi Arabia
      13.2.2. South Africa
      13.2.3. UAE
      13.2.4. Rest of Middle East & Africa (MEA)
   13.3. Absolute $ Opportunity Assessment by Country
   13.4. Middle East & Africa Antihormonal Cancer Therapies Market Size and Volume Forecast by Application
      13.4.1. Breast Cancer
      13.4.2. Prostate Cancer
      13.4.3. Other
   13.5. Basis Point Share (BPS) Analysis by Application
   13.6. Y-o-Y Growth Projections by Application
   13.7. Middle East & Africa Antihormonal Cancer Therapies Market Size and Volume Forecast by Type
      13.7.1. Radiations
      13.7.2. Drugs
      13.7.3. Surgeries
      13.7.4. Others
   13.8. Basis Point Share (BPS) Analysis by Type
   13.9. Y-o-Y Growth Projections by Type
   13.10. Market Attractiveness/Growth Potential Analysis
      13.10.1. By Country
      13.10.2. By Product Type
      13.10.3. By Application
      13.10.4. By Sales Channel
   13.11. Middle East & Africa Antihormonal Cancer Therapies Demand Share, 2019-2026

14. Competition Landscape
   14.1. Global Antihormonal Cancer Therapies Market: Market Share Analysis
   14.2. Antihormonal Cancer Therapies Distributors and Customers
   14.3. Antihormonal Cancer Therapies Market: Competitive Dashboard
   14.4. Company Profiles (Details – Overview, Financials, Developments, Strategy) 
      14.4.1. AstraZeneca
         14.4.1.1. Overview
         14.4.1.2. Financials
         14.4.1.3. Developments
         14.4.1.4. Strategic Outlook
      14.4.2. Novartis
         14.4.2.1. Overview
         14.4.2.2. Financials
         14.4.2.3. Developments
         14.4.2.4. Strategic Outlook
      14.4.3. Pfizer
         14.4.3.1. Overview
         14.4.3.2. Financials
         14.4.3.3. Developments
         14.4.3.4. Strategic Outlook
      14.4.4. Sanofi
         14.4.4.1. Overview
         14.4.4.2. Financials
         14.4.4.3. Developments
         14.4.4.4. Strategic Outlook
      14.4.5. Takeda
         14.4.5.1. Overview
         14.4.5.2. Financials
         14.4.5.3. Developments
         14.4.5.4. Strategic Outlook
      14.4.6. Roche
         14.4.6.1. Overview
         14.4.6.2. Financials
         14.4.6.3. Developments
         14.4.6.4. Strategic Outlook
      14.4.7. Amgen
         14.4.7.1. Overview
         14.4.7.2. Financials
         14.4.7.3. Developments
         14.4.7.4. Strategic Outlook
      14.4.8. Samyang Biopharmaceuticals
         14.4.8.1. Overview
         14.4.8.2. Financials
         14.4.8.3. Developments
         14.4.8.4. Strategic Outlook
      14.4.9. Tolmar
         14.4.9.1. Overview
         14.4.9.2. Financials
         14.4.9.3. Developments
         14.4.9.4. Strategic Outlook
      14.4.10. Bluebird Bio
         14.4.10.1. Overview
         14.4.10.2. Financials
         14.4.10.3. Developments
         14.4.10.4. Strategic Outlook
      14.4.11. Bristol-Myers Squibb
         14.4.11.1. Overview
         14.4.11.2. Financials
         14.4.11.3. Developments
         14.4.11.4. Strategic Outlook
      14.4.12. Exelixis
         14.4.12.1. Overview
         14.4.12.2. Financials
         14.4.12.3. Developments
         14.4.12.4. Strategic Outlook
      14.4.13. Guardant Health
         14.4.13.1. Overview
         14.4.13.2. Financials
         14.4.13.3. Developments
         14.4.13.4. Strategic Outlook
      14.4.14. Illumina
         14.4.14.1. Overview
         14.4.14.2. Financials
         14.4.14.3. Developments
         14.4.14.4. Strategic Outlook
      14.4.15. COMPANY 15
         14.4.15.1. Overview
         14.4.15.2. Financials
         14.4.15.3. Developments
         14.4.15.4. Strategic Outlook
      14.4.16. COMPANY 16
         14.4.16.1. Overview
         14.4.16.2. Financials
         14.4.16.3. Developments
         14.4.16.4. Strategic Outlook
      14.4.17. COMPANY 17
         14.4.17.1. Overview
         14.4.17.2. Financials
         14.4.17.3. Developments
         14.4.17.4. Strategic Outlook
      14.4.18. COMPANY 18
         14.4.18.1. Overview
         14.4.18.2. Financials
         14.4.18.3. Developments
         14.4.18.4. Strategic Outlook
      14.4.19. COMPANY 19
         14.4.19.1. Overview
         14.4.19.2. Financials
         14.4.19.3. Developments
         14.4.19.4. Strategic Outlook
      14.4.20. COMPANY 20
         14.4.20.1. Overview
         14.4.20.2. Financials
         14.4.20.3. Developments
         14.4.20.4. Strategic Outlook

Our Trusted Clients

Contact Us